A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

NCT00811135 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: bevacizumab [Avastin]
DRUG: capecitabine [Xeloda]
DRUG: trastuzumab [Herceptin]

Sponsor

Hoffmann-La Roche